GlaxoSmithKline is a science-led global healthcare company on a mission to help people do more, feel better and live longer. The Company has three world-leading businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. GlaxoSmithKline manufactures products for major disease areas such as asthma, cancer, infections, diabetes and mental health. 

Brentford, GB
Size (employees)
99,827 (est)
GlaxoSmithKline was founded in 2001 and is headquartered in Brentford, GB
Report incorrect company information

Key People/Management at GlaxoSmithKline

Simon Dingemans

Simon Dingemans

Chief Financial Officer
David Redfern

David Redfern

Chief Strategy Officer
Roger Connor

Roger Connor

President, Global Manufacturing & Supply
Luc Debruyne

Luc Debruyne

President, Global Vaccines
Nick Hirons

Nick Hirons

Senior Vice President, Global Ethics and Compliance
Brian McNamara

Brian McNamara

CEO, GSK Consumer Healthcare
Luke Miels

Luke Miels

President, Global Pharmaceuticals
Karenann Terrell

Karenann Terrell

Chief Digital & Technology Officer
Claire Thomas

Claire Thomas

Senior Vice President, Human Resources
Phil Thomson

Phil Thomson

President, Global Affairs
Patrick Vallance

Patrick Vallance

Outgoing President, R&D
Emma Walmsley

Emma Walmsley

Chief Executive Officer of GSK
Hal Barron

Hal Barron

Chief Scientific Officer and President, R&D
Dan Troy

Dan Troy

Senior Vice President & General Counsel

GlaxoSmithKline Office Locations

GlaxoSmithKline has an office in Boudouaou Est, Tirana, Yerevan, Boronia and in 145 other locations
Brentford, GB (HQ)
980 Great West Road
Tirana, AL
Str. Barrikadave No. 118
Boudouaou Est, DZ
Boumerdes, 35 400
Buenos Aires, AR
GlaxoSmithKline Argentina SA, Carlos Casares 3690, Victoria
Yerevan, AM
7 Baghramian Avenue, Flat 3
Boronia, AU
1061 Mountain Highway
Show all (149)
Report incorrect company information

GlaxoSmithKline Financials and Metrics

GlaxoSmithKline Financials

GlaxoSmithKline's revenue was reported to be £27.89 b in FY, 2016 which is a 16.6% increase from the previous period.

Revenue (FY, 2016)

27.9 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

18.6 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

1.1 b

Market capitalization (2-Oct-2017)

89 b

Closing share price (2-Oct-2017)


Cash (0-Mar-2018)

4.9 b
GlaxoSmithKline's current market capitalization is $89 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


26.5 b23 b23.9 b27.9 b

Revenue growth, %


Cost of goods sold

8.6 b7.3 b8.9 b9.3 b

Gross profit

17.9 b15.7 b15.1 b18.6 b
GBPFY, 2013FY, 2014FY, 2015FY, 2016


5.5 b4.3 b5.8 b4.9 b

Accounts Receivable

4 b3.6 b3.9 b4.7 b

Current Assets

15.2 b14.7 b16.6 b16.7 b


13.4 b13.9 b15 b17.6 b
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

2.6 b5.2 b7.2 b6.5 b

Cash From Financing Activities

(6.3 b)(5.4 b)(7.1 b)(6.4 b)

Income Taxes Paid

(1 b)(137 m)(2.2 b)(877 m)
GBPY, 2016


279.4 k

Financial Leverage

52.6 x
Show all financial metrics

GlaxoSmithKline Operating Metrics

GlaxoSmithKline's Unique Visitors was reported to be 1.8 m in FY, 2016.
FY, 2015FY, 2016FY, 2017


100 100 100

Manufacturing Facilities

57 54 87


150 150 150

New Product Launches

50 40 30
Show all operating metrics
Report incorrect company information